GET DAILY SIGNALSWhy Is Exagen (XGN) Stock Up +18.93% Today?
Key Takeaways
- XGN shares rallied roughly 18.93% in Monday's session, rebounding from a steep multi-day selloff.
- The move appears driven by bargain hunting and short covering as traders position ahead of the company's third-quarter earnings report.
- A bullish analyst backdrop, including recent price-target increases, is lending support to the bounce.
- The rebound follows sharp losses late last week, when the stock fell from above $8 to close at $5.81.
- Investors are watching Exagen's Q3 results, scheduled for release before the market opens on Tuesday, November 10.
- You can explore additional Price Targets, Earnings data, and Forecast pages for deeper analysis.
- For automated trading ideas, explore the latest Trending AI Robots.
Opening Summary
Exagen Inc. (XGN), a Carlsbad, California-based provider of autoimmune diagnostics best known for its AVISE CTD testing platform, saw its stock surge in Monday's session. Shares climbed 18.93% to $6.91, up from the prior session's closing price of $5.81. The advance marked a sharp reversal after several consecutive sessions of heavy selling, and it comes just one day before the company is set to report third-quarter financial results.
A Rebound After a Steep Selloff
The most immediate driver behind the move was a technical and sentiment rebound. Exagen stock had tumbled from roughly $8.50 earlier in the prior week to close at $5.81 on Friday, a decline accompanied by unusually heavy trading volume. Monday's sharp bounce suggests investors stepped back in to capitalize on depressed valuations, with short covering and dip buying amplifying the upward pressure. When a small-cap stock falls rapidly, a subsequent snap-back rally can be especially pronounced as sellers exhaust themselves and momentum traders reverse position.
Positioning Ahead of Third-Quarter Earnings
Exagen is scheduled to report results for the quarter ended September 30, 2026, before the market opens on Tuesday, November 10. With the report just hours away, the price action reflects traders establishing or adjusting positions ahead of the announcement. Exagen has a recent track record of beating consensus estimates: in its second-quarter report, it posted a narrower-than-expected loss and record quarterly revenue, then raised its full-year revenue guidance to between $72 million and $75 million. That history of execution is providing a degree of optimism heading into the upcoming print.
Analyst Support and Strong Fundamentals
The rebound is also occurring against a backdrop of broadly constructive analyst sentiment. Several research firms raised their price targets on Exagen in recent months, with targets moving to the $9 to $12 range amid Buy ratings, and the consensus rating on the stock stands at Strong Buy. Fundamentally, the company has posted record revenue, record AVISE CTD test volume, and thirteen consecutive quarters of growth in average selling price, while narrowing its adjusted EBITDA loss to near breakeven in the most recent quarter. These factors give investors a favorable narrative to lean on as the stock recovers.
Market Context and Trading Activity
Monday's move stood in contrast to the prior week's weakness and highlighted the volatility typical of small-cap healthcare and diagnostics names. Volume had spiked dramatically during the selloff, and the subsequent rebound indicates active two-way trading rather than a quiet drift higher. The stock remains below its fifty-day moving average, underscoring that despite the sharp single-day gain, the broader technical picture is still in recovery mode. The move was largely company-specific, with no single macro catalyst clearly driving the reversal.
What Comes Next for XGN
The next major checkpoint for XGN is Tuesday's third-quarter earnings release, where investors will focus on revenue growth, AVISE test volume, average selling price trends, and any update to full-year guidance. Management has cautioned that adjusted EBITDA may not sustain near-breakeven levels in the second half of the year due to typical seasonality. Risks to monitor include reimbursement uncertainty tied to a pending Medicare local coverage determination, variability in cash collections, and the timing of the planned myositis product launch in early 2027. While analyst sentiment remains favorable, the stock's sharp two-way swings highlight that volatility is likely to persist around near-term catalysts.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a range of automated approaches to consider. Explore the Trending AI Robots page to discover which strategies are currently gaining traction.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.
XGN in upward trend: 10-day moving average broke above 50-day moving average on November 02, 2026
The 10-day moving average for XGN crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for XGN's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
Following a +11.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where XGN advanced for three days, in 190 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
XGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 159 of 185 cases where XGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 45 cases where XGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 84%.
The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XGN as a result. In 80 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for XGN turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In 33 of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
XGN moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.522) is normal, around the industry mean (67.298). P/E Ratio (-7.085) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.592) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating fairly steady price growth. XGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 76 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases
Industry MedicalSpecialties
Advertisement